Venlafaxine Pathway published in PG&G

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed for the treatment of depression disorders.
We recently have published the Venlafaxine Pathway summary in the Pharmacogenetics and Genomics Journal.The article describes the metabolism of venlafaxine, with cytochrome P450 2D6 (CYP2D6) being the major enzyme involved in the formation of its metabolites. The pharmacokinetics of venlafaxine is affected by the CYP2D6 metabolizer phenotype.

Read the article for a discussion about the influence of genetic variations on venlafaxine metabolism and treatment outcome.

Find out more...

View the venlafaxine pathway on PharmGKB.

Read the publication:
PharmGKB summary: venlafaxine pathway.Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE.Pharmacogenet Genomics. 2013 Oct 14 PMID: 24128936

View all pathways on PharmGKB.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.